The discovery of novel and disease-specific serum anti-aquaporin (AQP) 4 antibodies has clearly identified NMO as a separate disease entity from MS, and suggested that AQP4 is a specific immunological target in NMO [3]. The gene discussed is AQP4; the disease is myeloid sarcoma.